oncology I Flashcards
breast cancer screening
40-44 annual optional
45-54 begin yearly mammograms
>=55 years mammograms every 2 years or continue yearly
cervical
21-29 pap smear every 3 years
30-65 pap smear +HPV DNA test every 5 years
colon
> = 45 stool-based tests- if positive, follow-up w/ colonoscopy, every 3 years
colonoscopy every 10 years
dosing considerations for select highly drugs
Bleomycin
Lifetime cumulative dose: 400 units
reason: pulmonary toxicity
dosing considerations for select highly drugs
Doxorubicin
lifetime cumulative dose: 450-550 mg/m^2
reason: cardiotoxicity
Cisplatin
dose per cycle not to exceed 100mg/m^2
reason: nephrotoxicity
Vincristine
single dose “capped” at 2mg
reason: neuropathy
all pt prego and breastfeeding
all pt regardless of gender must avoid conceiving during tx
N- nitrosoureas
Lomustine, carmustine
neurotoxicity
C- Platinum-based
Cisplatin, Carboplatin
nephrotoxic/ototoxic
M- methotrexate
mucositis
B- Bleomycin, Busulfan, Carmustine, Lomustine
Pulmonary Fibrosis
D- Doxorubicin & other anthracyclines
cardiotoxic
AI- Immunotherapy
targeting CTLA-4 or PDL-1: ipilimumab, atezolizumab, durvalumab, nivolumab, pembrolizumab
autoimmune syndromes (widespread effects)
IP- ifosfamide & cyclophosphamide
Hemorrhagic cystitis
VT- vinca alkaloids and taxanes
vinca alkaloids (vincristine, vinblastine & vinorelbine) and Taxanes (paclitaxel, docetaxel)
peripheral neuropathy
BMS- bone marrow suppression
common toxicity of many chemotherapy agents including: alkylators, anthracyclines, platinum-based compounds (cisplatin), taxanes, topoisomerase I and II inhibitors, antimetabolites and vinca alkaloids (vinblastine and vinorelbine)
chemotherapy adjunctive tx
cisplatin
amifostine (ethyol) and hydration
prophylaxis to prevent nephrotoxicity
chemotherapy adjunctive tx
doxorubicin
dexrazoxane (totect)
prophylaxis to prevent cardiomayopathy
chemotherapy adjunctive tx
fluorouracil
leucovorin or levoleucovorin
given w/ fluorouracil to enhance efficacy (as a cofactor)
chemotherapy adjunctive tx
fluorouracil or capecitabine
uridine triacetate
antidote: use within 96 hrs for an over dose or to tx severe, life-threatening or early-onset of tox
ifosfamide
Mesna (Mesnex) and hydration
prophylaxis to prevent hemorrhagic cystitis
irinotecan
atropine- prevent or treat acute diarrhea
loperamide- treat delayed diarrhea
methotrexate
leucovorin or levoleucovorin- given prophylactically after high-dose methotrexate to decrease myelosuppression and mucositis
glucarpidase- an antidote to decrease excessive methotrexate levels due to acute renal failure
myelosuppression- three major groups
red blood cells
platelets
white blood cells
myelosuppression
red blood cells
- decrease in RBC- anemia (decrease in Hgb/Hct)
- symptoms: weakness/fatigue
- can resolve on its own or with an RBC transfusion
Drug tx:
- erythropoiesis-stimulating agents (ESA)
—> epoetin alfa (epogen, procrit)
—> darbepoetin alfa (Aranesp)
myelosuppression
platelets
- decrease platelets- causing thrombocytopenia
- symptom: bleeding
- platelet transfusion, if platelets are very low (<10,000 cells/mm^3)
myelosuppression
white blood cells
- decrease WBC- means leukopenia (decreased immune response)
- symptoms: fever/infection
drug tx:
- colony-stimulating factors (CSF)
—> filgrastim (Neupogen)
—> pegfilgrastim (Neulasta)
WBC nadir
lowest point in WBC which occurs about 7-14 days after chemotherapy
RBC nadir
lowest point in RBC
generally after several months of tx, due to the long life-span of RBC (120 days average)
WBCs and platelets generally recover
3-4 weeks post tx. the next dose of chemothera[y is given after the WBCs and platelets and return to a safe level
next cycle can be delayed to give more time to recover
neutropenia
<1,000 cells/mm^3
severe neutropenia
< 500 cells/mm^3
profound neutropenia
<100 cells/mm^3